Japan Chemical Research Raises Stakes In Antibody Firm BioMatrix
This article was originally published in PharmAsia News
Executive Summary
Hygo Prefecture-based drug maker Japan Chemical Research increased its holding shares from 8.8 percent to 39.9 percent in Chiba Prefecture-based biotech venture BioMatrix Research. Supported by the Tokyo Institute of Industry and a research partner for JCR, BioMatrix analyzes DNA sequencing and conducts monoclonal antibody research. JCR aims to develop more effective antibody medicines through combining BMR expertise in antibody manufacturing technology. (Click here for more - Japanese language